Genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 January 2023 until 31 August 2023 informed the WHO influenza vaccine composition meeting (VCM) in September 2023 when recommendations were made for the southern hemisphere (SH) 2024 influenza season.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 28 January - 3 February 2024 and includes updates on SARS-CoV-2 variant classification, swine influenza, human cases of co-infection with seasonal influenza and avian influenza, influenza, western equine encephalitis, and an overview of respiratory virus epidemiology in the EU/EEA.
This report presents the available data for describing the current situation regarding HIV prevalence among sex workers, and the efforts being made across Europe and Central Asia towards HIV prevention among this population.
This report contains genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 January 2023 until 31 August 2023.
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.
Lymphogranuloma venereum (LGV) is a systemic sexually transmitted infection (STI) caused by Chlamydia trachomatis serovars L1, L2, or L3. In 2021, 1 124 cases of LGV were reported by 23 EU/EEA Member States.
For 2021, 27 EU/EEA Member States reported 184 542 confirmed cases of chlamydia infection. The crude notification rate was 74 cases per 100 000 population.